drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous CD7-directed chimeric antigen receptor (CAR) T-cell therapy. Patient T cells are engineered to express a CD7-targeted CAR (CD3ζ with costimulation); upon CD7 engagement, CAR signaling activates and expands T cells to kill CD7+ malignant cells via perforin/granzyme and cytokine-mediated cytotoxicity in r/r T-ALL, lymphoblastic lymphoma, and CD7-positive AML.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a CD7-directed chimeric antigen receptor (with CD3ζ signaling and costimulatory domains). Upon binding CD7 on malignant cells, CAR activation drives T‑cell activation, expansion, and cytotoxic killing via perforin/granzyme release and cytokine-mediated mechanisms, depleting CD7+ leukemic/lymphoma cells.
drug_name
RD13-02 cell infusion
nct_id_drug_ref
NCT05895994